Last Updated:
10 Mar 2026, 03:30:03 PM (IST)
Akums Drugs & Pharmaceuticals Ltd.
NSE: AKUMS
NSE
500.60
21.00 (4.38%)
Prev Close
479.6
Open Price
479.6
Volume
265,090
Today Low / High
479.6 / 503
52 WK Low / High
405 / 622.95
Range
476 - 526
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 500.6, with a change of 21 (4.37865%). The expected target range on the NSE is between 476 - 526. The stock is trending upwards on the NSE, which could present a good opportunity for potential investors.
02 Mar
472.00
0.52%
27 Feb
474.25
2.93%
26 Feb
478.10
0.82%
25 Feb
483.20
-1.08%
24 Feb
474.50
1.81%
23 Feb
478.80
-0.90%
20 Feb
484.80
-1.25%
19 Feb
497.40
-2.17%
Akums Drugs & Pharmaceuticals Ltd. Graph
Akums Drugs & Pharmaceuticals Ltd. Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Akums Drugs & Pharmaceuticals Ltd. T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 500.60, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 500.60 | 505.61 | 455.05 - 556.17 |
| 510.61 | 408.49 - 612.73 | ||
| 515.62 | 360.93 - 670.30 | ||
| Bearish Scenario | 500.60 | 495.59 | 446.03 - 545.15 |
| 490.59 | 392.47 - 588.71 | ||
| 485.58 | 339.91 - 631.26 |
Overview of Akums Drugs & Pharmaceuticals Ltd.
ISIN
INE09XN01023
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
247,910
Market Cap
72,639,271,418
Last Dividend
0
Official Website
IPO Date
2024-08-06
DCF Diff
-175.44
DCF
650
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,071.09 Cr | 2,465.74 Cr | 1,605.36 Cr | 0.3943 | 0.00 Cr | 47.21 Cr | 310.65 Cr | 338.18 Cr | 22.60 | 529.11 Cr | 0.0831 |
| 2024-03-31 | 4,019.68 Cr | 2,582.22 Cr | 1,437.46 Cr | 0.3576 | 0.00 Cr | 50.51 Cr | 359.90 Cr | -4.04 Cr | -0.28 | 130.61 Cr | -0.0010 |
| 2023-03-31 | 3,474.76 Cr | 2,307.47 Cr | 1,167.29 Cr | 0.3359 | 0.00 Cr | 52.12 Cr | 191.31 Cr | 94.86 Cr | 6.03 | 309.08 Cr | 0.0273 |
| 2022-03-31 | 3,646.83 Cr | 2,377.83 Cr | 1,269.00 Cr | 0.3480 | 0.00 Cr | 35.89 Cr | 322.21 Cr | -252.54 Cr | -16.04 | -82.18 Cr | -0.0692 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 101.19 Cr | 4,113.44 Cr | 1,049.83 Cr | 3,047.0140 Cr | 88.21 Cr | -12.98 Cr | 680.93 Cr | 1,563.65 Cr | 0.00 Cr | 13.68 Cr | 0.00 Cr | 893.7470 Cr |
| 2024-03-31 | 111.05 Cr | 3,516.37 Cr | 2,795.88 Cr | 709.4980 Cr | 565.23 Cr | 454.18 Cr | 630.43 Cr | 1,390.67 Cr | 0.00 Cr | 13.14 Cr | 0.00 Cr | 1,210.5520 Cr |
| 2023-03-31 | 51.61 Cr | 3,266.53 Cr | 2,543.15 Cr | 717.1890 Cr | 619.09 Cr | 567.49 Cr | 729.80 Cr | 1,212.31 Cr | 0.00 Cr | 15.19 Cr | 0.00 Cr | 1,265.5670 Cr |
| 2022-03-31 | 55.14 Cr | 3,069.05 Cr | 2,443.88 Cr | 621.9760 Cr | 394.98 Cr | 339.84 Cr | 722.45 Cr | 1,059.94 Cr | 0.00 Cr | 11.34 Cr | 0.00 Cr | 1,272.4180 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 465.1960 Cr | -547.8430 Cr | 72.7880 Cr | 192.8840 Cr | -9.8590 Cr | 101.1910 Cr | -272.3120 Cr | 345.2530 Cr | -477.9000 Cr | 0.0000 Cr | -50.5710 Cr |
| 2024-03-31 | 498.2590 Cr | -330.4150 Cr | -108.0210 Cr | 186.8510 Cr | 59.4420 Cr | 111.0500 Cr | -311.4080 Cr | -45.2780 Cr | -49.1910 Cr | 0.0000 Cr | 83.7290 Cr |
| 2023-03-31 | 176.6310 Cr | -304.7020 Cr | 124.5400 Cr | -152.1620 Cr | -3.5310 Cr | 51.6080 Cr | -328.7930 Cr | 150.2970 Cr | 177.9810 Cr | 0.0000 Cr | -7.3470 Cr |
| 2022-03-31 | 31.8540 Cr | -234.8220 Cr | 236.0400 Cr | -225.7280 Cr | 33.0720 Cr | 55.1390 Cr | -257.5820 Cr | -193.1970 Cr | 261.3230 Cr | 0.0000 Cr | -292.5890 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 1,159.59 Cr | 907.61 Cr | 251.98 Cr | 0.2173 | 107.21 Cr | 66.32 Cr | 4.33 | 146.86 Cr | 0.0572 |
| 2025-09-30 | 1,017.53 Cr | 592.56 Cr | 424.97 Cr | 0.4176 | 56.61 Cr | 40.78 Cr | 2.66 | 123.44 Cr | 0.0401 |
| 2025-06-30 | 1,024.03 Cr | 581.92 Cr | 442.12 Cr | 0.4317 | 92.05 Cr | 63.48 Cr | 4.15 | 150.83 Cr | 0.0620 |
| 2025-03-31 | 1,008.48 Cr | 671.39 Cr | 337.09 Cr | 0.3343 | 57.40 Cr | 147.62 Cr | 0.00 | 115.48 Cr | 0.1464 |
| 2024-12-31 | 1,010.41 Cr | 602.39 Cr | 408.02 Cr | 0.4038 | 76.85 Cr | 65.18 Cr | 4.26 | 140.71 Cr | 0.0645 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 229.10 Cr | 1,448.72 Cr | 1,677.82 Cr | 746.23 Cr | 648.36 Cr | 3,293.49 Cr | 1,568.04 Cr | 5,159.29 Cr | 1,990.86 Cr |
| 2025-03-31 | 101.19 Cr | 480.76 Cr | 581.95 Cr | 778.05 Cr | 680.93 Cr | 2,274.61 Cr | 1,563.65 Cr | 4,113.44 Cr | 1,049.83 Cr |
| 2024-09-30 | 482.00 Cr | 342.29 Cr | 824.29 Cr | 949.31 Cr | 659.60 Cr | 2,623.60 Cr | 1,412.70 Cr | 4,270.40 Cr | 1,423.42 Cr |
| 2024-03-31 | 111.05 Cr | 176.77 Cr | 287.82 Cr | 833.81 Cr | 630.43 Cr | 1,940.88 Cr | 1,390.67 Cr | 3,516.37 Cr | 2,795.88 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| No quarterly financial cash flow statement data available. | |||||||||
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
President of Human Resource
Arvind Srivastava
Gender: male
Year Born:
Company Secretary & Compliance Officer
Dharamvir Malik
Gender: male
Year Born:
Co Founder, MD & Director
Sandeep Jain
Gender: male
Year Born: 1967
President of Operations & Whole Time Director
Sanjay Kumar Sinha
Gender: male
Year Born: 1958
President of Strategy, New Projects & Business Excellence
Sanjay Sharma
Gender: male
Year Born:
President of CQA Formulation
Shantanu R. Chobhe
Gender: male
Year Born:
Chief Financial Officer
Sumeet Sood
Gender: male
Year Born:
Director of Corporate Growth & Excellence
Arushi Jain
Gender: female
Year Born:
General Manager of Strategy
Sahil Maheshwari
Gender: Not Specified
Year Born:
Co-Founder, MD & Whole Time Director
Sanjeev Jain
Gender: male
Year Born: 1966
FAQs about Akums Drugs & Pharmaceuticals Ltd.
Who is the CEO of the company?
The CEO is Sanjeev Jain.
What is the current market price of the stock?
The current price is ₹474.45.
What is the 52-week price range?
The range is ₹405-622.95.
What is the market capitalization of the company?
The market capitalization is ₹7,263.93 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 22.83.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Akums Drugs & Pharmaceuticals Ltd. (ISIN: INE09XN01023) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹7,263.93 crores and an average daily volume of 247,910 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.